Harte-Hanks revamps digital practice

Share this article:
Harte-Hanks' Glen Hartman
Harte-Hanks' Glen Hartman

Harte-Hanks has announced a series of changes and promotions as it enhances its digital practice area.

Glen Hartman has been promoted to managing director of the digital practice.

Previously, Hartman led Harte-Hanks as an SVP for digital marketing for data-based marketing solutions. In his new role, Hartman is responsible for managing all aspects of the digital practice and its offerings including web site development, online advertising, search engine marketing, e-mail, mobile messaging, Web analytics and social networking.

In addition, the digital practice has added to its management team with several new hires. These hires include Julie Donovan, VP/practice leader, digital media; Thomas Molitor, VP/practice leader, digital interaction; Gary Druckenmiller Jr., VP, strategy & business development, digital practice.

“The Harte-Hanks digital practice has grown considerably throughout the past year,” Frank Harvey, corporate officer and VP said in a statement. “While this growth represents the increasing importance of digital media and marketing, it also represents the value of our digital expertise including the understanding we provide to our clients about how digital applications and their successful executions feed a larger multichannel strategy.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...